Class I and II HLA antibodies in pediatric patients with thalassemia major-Reference-Cited by-同舟云学术

Class I and II HLA antibodies in pediatric patients with thalassemia major

Published:2015-12-15 Issue:4 Volume:56 Page:878-884
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Yee Marianne E. McPherson¹²,Shah Ankoor³,Anderson Alan R.⁴,Boudreaux Jeanne¹²,Bray Robert A.⁵,Gebel Howard M.⁵,Josephson Cassandra D.²⁵

Affiliation:

1. Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta

2. Department of Pediatrics and Hematology/Oncology

3. Department of Pediatrics; Children's National Medical Center; Washington DC

4. Pediatric Hematology/Oncology; BI-LO Charities Children's Cancer Center, Greenville Health System; Greenville South Carolina.

5. Pathology and Laboratory Medicine; Emory University; Atlanta Georgia

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/trf.13440/fullpdf

Reference46 articles.

1. Multiple red cell transfusions and alloimmunization. Experience with 6996 antibodies detected in a total of 159,262 patients from 1985 to 1993;Hoeltge;Arch Pathol Lab Med,1995

2. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood;Vichinsky;N Engl J Med,1990

3. Alloimmunization in two multitransfused patient populations;Coles;Transfusion,1981

4. A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion;Heddle;Br J Haematol,1995

5. Red cell alloantibodies in patients with thalassemia;Spanos;Vox Sang,1990

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs;International Journal of Molecular Sciences;2023-11-25

2. High-Dose immunoglobulin Intervention as an effective and simple strategy for donor specific Anti-HLA antibody desensitization in haploidentical transplant;International Immunopharmacology;2023-07

3. Major histocompatibility complex (MHC) antigens polymorphism and alloimmunization study in thalassemia patients with febrile non-hemolytic transfusion reaction (FNHTR);Transfusion Clinique et Biologique;2023-05

4. Human leukocyte antigen immunization in transfusion-dependent Moroccan patients with beta-thalassemia major: prevalence and risk factors;Hematology, Transfusion and Cell Therapy;2023-05

5. Hematopoietic Stem Cell Transplantation in Thalassemia;Hematology/Oncology Clinics of North America;2023-04